Surface Oncology, Inc. (NASDAQ:SURF) CEO Robert W. Ross Sells 10,594 Shares of Stock

Surface Oncology, Inc. (NASDAQ:SURFGet Rating) CEO Robert W. Ross sold 10,594 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $1.72, for a total transaction of $18,221.68. Following the completion of the transaction, the chief executive officer now directly owns 99,906 shares of the company’s stock, valued at $171,838.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Surface Oncology Price Performance

Shares of NASDAQ:SURF opened at $1.78 on Friday. The firm has a fifty day moving average price of $1.80 and a two-hundred day moving average price of $2.48. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.19 and a quick ratio of 9.42. Surface Oncology, Inc. has a one year low of $1.37 and a one year high of $8.38.

Surface Oncology (NASDAQ:SURFGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.48) by $0.61. Surface Oncology had a negative net margin of 182.63% and a negative return on equity of 48.17%. The firm had revenue of $30.00 million during the quarter. As a group, equities analysts anticipate that Surface Oncology, Inc. will post -1.19 EPS for the current year.

Analysts Set New Price Targets

Separately, Jonestrading reissued a “buy” rating and issued a $12.00 price target on shares of Surface Oncology in a report on Sunday, June 5th.

Institutional Trading of Surface Oncology

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $27,000. Formidable Asset Management LLC purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $33,000. Delphia USA Inc. purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $36,000. Forefront Analytics LLC purchased a new stake in shares of Surface Oncology during the 1st quarter valued at $62,000. Finally, JPMorgan Chase & Co. raised its position in shares of Surface Oncology by 26.4% during the 1st quarter. JPMorgan Chase & Co. now owns 22,082 shares of the company’s stock valued at $65,000 after buying an additional 4,611 shares in the last quarter. Hedge funds and other institutional investors own 70.81% of the company’s stock.

About Surface Oncology

(Get Rating)

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.

Read More

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.